Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Brain Cancer Diagnostics Market to Register Immense Growth at a CAGR of ~10% by 2034 | DelveInsight

globenewswire.com
BMY Mentioned as a key company in the brain cancer diagnostics market, but no specific sentiment or performance data is provided in the article. AZN Mentioned as a key company in the brain cancer diagnostics market, but no specific sentiment or performance data is provided in the article. JNJ Mentioned as a key company in the brain cancer diagnostics market, but no specific sentiment or performance data is provided in the article. MRK Mentioned as a key company in the brain cancer diagnostics market and biomarkers market, but no specific sentiment or performance data is provided. PFE Mentioned as a key company in the brain cancer diagnostics market, but no specific sentiment or performance data is provided in the article. RDY Mentioned as a key company in the brain cancer diagnostics market, but no specific sentiment or performance data is provided in the article. GNTA Mentioned as a key company in the glioblastoma market, but no specific sentiment or performance data is provided in the article. MIMI Mentioned as a key company in the glioblastoma market, but no specific sentiment or performance data is provided in the article. CNS Mentioned as a key company in the glioblastoma market, but no specific sentiment or performance data is provided in the article. GEHC Mentioned as a key company in the diagnostic imaging equipment market, but no specific sentiment or performance data is provided in the article. PHG Mentioned as a key company in the diagnostic imaging equipment market, but no specific sentiment or performance data is provided in the article. HOG Mentioned as a key company in the diagnostic imaging equipment market and molecular diagnostics market, but no specific sentiment or performance data is provided. HSIC Mentioned as a key company in the diagnostic imaging equipment market, but no specific sentiment or performance data is provided in the article. VMI Mentioned as a key company in the diagnostic imaging equipment market, but no specific sentiment or performance data is provided in the article. MIND Mentioned as a key company in the diagnostic imaging equipment market, but no specific sentiment or performance data is provided in the article. ABT Mentioned as a key company in the molecular diagnostics market and biomarkers market, but no specific sentiment or performance data is provided. QGEN Mentioned as a key company in the molecular diagnostics market and biomarkers market, but no specific sentiment or performance data is provided. BDX Mentioned as a key company in the molecular diagnostics market, but no specific sentiment or performance data is provided in the article. TMO Mentioned as a key company in the molecular diagnostics market, but no specific sentiment or performance data is provided in the article. DHR Mentioned as a key company in the molecular diagnostics market, but no specific sentiment or performance data is provided in the article. MYGN Mentioned as a key company in the molecular diagnostics market, but no specific sentiment or performance data is provided in the article. ILMN Mentioned as a key company in the molecular diagnostics market, but no specific sentiment or performance data is provided in the article. EXAS Mentioned as a key company in the molecular diagnostics market, but no specific sentiment or performance data is provided in the article. MDXH Mentioned as a key company in the molecular diagnostics market, but no specific sentiment or performance data is provided in the article. LAB Mentioned as a key company in the biomarkers market, but no specific sentiment or performance data is provided in the article. LH Mentioned as a key company in the biomarkers market, but no specific sentiment or performance data is provided in the article. BIO Mentioned as a key company in the biomarkers market, but no specific sentiment or performance data is provided in the article. BIIB Mentioned as a key company in the biomarkers market, but no specific sentiment or performance data is provided in the article.

Brain Cancer Diagnostics Market to Register Immense Growth at a CAGR of ~10% by 2034 | DelveInsight New York, USA, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Diagnostics Market to Register Immense Growth at a CAGR of ~10% by 2034 | DelveInsight

The global brain cancer diagnostics market was valued at USD 4.10 billion in 2025 and is projected to reach USD 9.85 billion by 2034, according to DelveInsight's latest brain cancer diagnostics Market Insights report.

The market is expected to grow at a CAGR of 10.2% during the forecast period (2026–2034), driven by the rising incidence of primary and metastatic brain tumors, increasing adoption of advanced neuroimaging technologies, and growing demand for molecular and biomarker-based diagnostics. Imaging diagnostics accounted for 46% of the global market in 2025, making it the largest diagnostic segment, while glioblastoma represented 41% of the market by tumor type. North America dominated the global market with a 45% revenue share in 2025, whereas Asia-Pacific is anticipated to witness the fastest growth. Looking ahead, advancements in AI-assisted MRI and PET imaging, next-generation sequencing, liquid biopsy technologies, and biomarker-driven precision diagnostics are expected to shape the competitive landscape.

DelveInsight’s Brain Cancer Diagnostics Market Insights report provides the current and forecast market analysis, individual leading brain cancer diagnostics companies’ market shares, challenges, brain cancer diagnostics market drivers, barriers, trends, and key brain cancer diagnostics companies in the market.

Brain Cancer Diagnostics Market Summary

Source: DelveInsight, Brain Cancer Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2034.

Market estimates are based on DelveInsight's research and forecasting methodology.

Request a free sample page to know the full forecast of the brain cancer diagnostics market @ https://www.delveinsight.com/report-store/brain-cancer-diagnostics-market

Himanshu Agnihotri, Project Manager of Healthcare Consulting at DelveInsight, said that the emergence of liquid biopsy, AI-powered imaging analysis, and advanced biomarker-based testing is creating new opportunities for early diagnosis and personalized treatment planning. Increasing investments in oncology research, expanding healthcare infrastructure, and growing demand for minimally invasive diagnostic approaches are expected to further accelerate market growth during the forecast period.

Key Factors Contributing to the Rise in Growth of the Brain Cancer Diagnostics Market

Get a sneak peek at the brain cancer diagnostics market dynamics @ Brain Cancer Diagnostics Market Trends

Regional Brain Cancer Diagnostics Market Insights

North America Brain Cancer Diagnostics Market Analysis

Europe Brain Cancer Diagnostics Market Analysis

Asia-Pacific Brain Cancer Diagnostics Market Analysis

To know more about why North America is leading the market growth in the brain cancer diagnostics market, get a snapshot of the Brain Cancer Diagnostics Market Analysis

Recent Developmental Activities in the Brain Cancer Diagnostics Market

What is Brain Cancer Diagnostics?

Brain cancer diagnostics refers to the range of medical procedures, imaging techniques, and laboratory tests used to detect, identify, classify, and monitor cancerous tumors in the brain. These diagnostic approaches play a critical role in determining tumor location, size, type, grade, and extent of progression, enabling clinicians to develop appropriate treatment strategies. Brain cancer diagnosis typically involves advanced imaging technologies, including magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET), which help visualize abnormal brain structures and assess tumor characteristics. Additionally, neurological examinations, tissue biopsy, histopathological analysis, molecular testing, and emerging liquid biopsy techniques are increasingly utilized to improve diagnostic accuracy and support personalized treatment decisions. Growing advancements in artificial intelligence (AI)-based imaging analysis, precision diagnostics, and molecular profiling are further enhancing early detection capabilities and contributing to the evolution of brain cancer diagnostics.

Brain Cancer Diagnostics Market Assessment

Which MedTech key players in the brain cancer diagnostics market are set to emerge as the trendsetter explore @ Brain Cancer Diagnostics Market Size

Table of Contents

Interested in knowing the brain cancer diagnostics market share by 2034? Click to get a snapshot of the Top Brain Cancer Diagnostics Companies

Related Reports

Brain Cancer Market

Brain Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key brain cancer companies, including Y-mAbs Therapeutics Inc., Shimadzu Corporation, Bristol-Myers Squibb, Bayer AG, AstraZeneca plc, Johnson & Johnson Inc., Merck & Co., Pfizer Inc., F. Hoffmann-La Roche Ltd, Dr. Reddy's Laboratories Ltd, and others.

Glioblastoma Market

Glioblastoma Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glioblastoma companies, including Laminar Pharmaceuticals, BioMimetix, Enterome, Genenta Science, Medicenna Therapeutics, Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Biotherapeutics, MedImmune, DNAtrix, Imvax, MimiVax, CNS Pharmaceuticals, Oblato, Enterome, VBI Vaccines, and others.

Diagnostic Imaging Equipment Market

Diagnostic Imaging Equipment Market Insights, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key diagnostic imaging equipment companies, including Siemens Healthineers, GE Healthcare, Philips Healthcare, Canon Medical Systems Corporation, Hitachi Medical Systems, Hologic, Inc., Shimadzu Corporation, Fujifilm Medical Systems, Carestream Health, Agfa-Gevaert Group, Esaote SpA, Samsung Healthcare, Toshiba Medical Systems Corporation (now part of Canon Medical Systems), Konica Minolta Healthcare, Varian Medical Systems, Ziehm Imaging GmbH, Mindray Medical International Limited, Planmed Oy, Analogic Corporation, Neusoft Medical Systems Co., Ltd., and others.

Molecular Diagnostics Market

Molecular Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key molecular diagnostics companies, including F. Hoffmann-La Roche Ltd, Hologic Inc., bioMerieux SA, Abbott Laboratories, QIAGEN N.V., Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher Corporation, and Myriad Genetics Inc. Additional participants including Agilent Technologies Inc., Illumina Inc., DiaSorin Inc., Exact Sciences Corporation, MDxHealth, Genetic Signatures, Biocartis, Amoy Diagnostics Co. Ltd., Molbio Diagnostics Pvt. Ltd., Savyon Diagnostics, and others.

Biomarkers Market

Biomarkers Market Insights, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key biomarkers companies, including F. Hoffmann-La Roche Ltd, Merck KGaA, Quibim, Quanterix, Abbott, QIAGEN, Revvity, Laboratory Corporation of America® Holdings, Charles River Laboratories., Bio-Rad Laboratories, Inc., Eurofins Scientific, BIOMÉRIEUX, Agilent Technologies, Inc., JSR Life Sciences, LLC, MESO SCALE DIAGNOSTICS, LLC., EKF Diagnostics, Celerion, Standard BioTools™, R-Biopharm AG, StressMarq Biosciences Inc., and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.